78742-98-0

Basic information

• Product Name: ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate
• Synonyms: ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate
• CAS NO: 78742-98-0
• Molecular Weight: 265.308
• Mol File: 78742-98-0.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate(78742-98-0)
• EPA Substance Registry System: ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate(78742-98-0)

Safety Data

• Hazardous Substances Data: 78742-98-0(Hazardous Substances Data)

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 22179-72-2 4-fluorothiobenzamide 

Downstream Products

• 78743-11-0 3-[2-(4-Fluoro-phenyl)-thiazol-4-yl]-4-hydroxy-pyrrole-2,5-dione 
• 78743-05-2 2-[2-(4-Fluoro-phenyl)-thiazol-4-yl]-acetamide 

Relevant articles and documents

METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES

Methods are provided for treating or preventing neurological symptoms and disorders which are associated with, e.g., lysosomal storage diseases. The methods include enhancing neuronal connectivity within the brain of a subject, increasing brain tissue volume, or preventing or delaying loss of brain tissue volume in a subject. Also provided are methods for monitoring the progression or regression of a neurological disorder, or assessing the onset of a neurological disorder, associated with a lysosomal storage disease, in which brain tissue volume of the subject is measured.

METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES

This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy. This includes pain, such as abdominal pain, and dermatological disorders, such as angiokeratoma, in a patient having a disease such as Fabry disease. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods.

METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.